Gilead Sciences Advances HIV Treatment with Promising Phase 3 Trial Results

Shares of Gilead Sciences are consolidating near the $120 level following significant clinical and financial developments. The company announced that its investigational once-daily oral combination of bictegravir and lenacapavir successfully met the primary endpoint in the Phase 3 ARTISTRY-2 trial. This news has prompted several analyst upgrades and comes on the heels of a strong quarterly earnings report.

Financial Performance and Analyst Sentiment

Gilead’s recent third-quarter results exceeded market expectations, posting earnings per share (EPS) of $2.47 against estimates of $2.16. Consequently, the company raised its full-year 2025 EPS guidance to a range of $8.05 to $8.25. The firm also maintains a robust dividend, with a payout of $0.79 per share scheduled for December 30, 2025, translating to a yield of approximately 2.6%.

Market researchers have responded positively to the combined news flow. Wolfe Research increased its price target on Gilead stock from $140 to $150, reiterating an Outperform rating. Similarly, Citi maintained a Buy recommendation with a $135 price objective. The current average consensus price target stands around $132, indicating potential upside from present trading levels.

Clinical Trial Success and Strategic Implications

The pivotal ARTISTRY-2 study evaluated the bictegravir/lenacapavir single-tablet regimen against the established therapy Biktarvy for maintaining virologic suppression in adults with HIV-1. The trial achieved its main goal, demonstrating non-inferiority with 48-week viral suppression (HIV-1 RNA <50 copies/mL). The combination therapy was reported to be generally well-tolerated, with no new significant safety concerns identified.

Should investors sell immediately? Or is it worth buying Gilead Sciences?

These findings support Gilead’s broader strategy to develop simplified oral maintenance regimens alongside its long-acting injectable portfolio. The data from ARTISTRY-2 and the related ARTISTRY-1 trial are intended to form the basis for regulatory submissions to health authorities worldwide. If approved, this new combination could serve as a patent-protected successor to Biktarvy, a cornerstone of Gilead’s HIV franchise.

Corporate Activity and Investor Considerations

Recent SEC filings revealed that two company insiders, CFO Andrew Dickinson and Johanna Mercier, each sold 3,000 shares at approximately $122 per share. These transactions were executed on the stock’s ex-dividend date.

Looking ahead, investors can monitor several near-term catalysts. The immediate focus will be on the regulatory filing process for the new HIV combination. Over the longer term, commercial success will depend on approval decisions and subsequent market adoption. The confirmed dividend payment in late December and future quarterly earnings reports provide additional tangible milestones for shareholders.